Autonomous Therapeutics, Inc.
Autonomous Therapeutics is pioneering new classes of nucleic acids to develop first-in-class medicines that are target-activated and variant-proof, aiming to end viral pandemics and treat metastatic cancers. The company is focused on encrypted RNA technology and has received funding from DARPA, NIH, BARDA, and other notable investors. It is committed to developing next-generation antivirals and therapeutics with a mission to create precision, resistance-proof immunity and innovative treatments.
Industries
Nr. of Employees
small (1-50)
Autonomous Therapeutics, Inc.
Products
Platform for variant-resistant nucleic acid therapeutics
A platform approach to design nucleic acid therapeutics that are target-activated and engineered for broad efficacy across viral variants, intended for prophylactic and therapeutic applications including respiratory delivery options.
Platform for variant-resistant nucleic acid therapeutics
A platform approach to design nucleic acid therapeutics that are target-activated and engineered for broad efficacy across viral variants, intended for prophylactic and therapeutic applications including respiratory delivery options.
Services
Collaborative R&D partnerships for antiviral and RNA therapeutic development
Collaborative research agreements and program partnerships with government agencies and industry to develop nucleic acid-based countermeasures and therapeutics.
Preclinical discovery and optimization services
End-to-end preclinical discovery services including protein engineering, nucleic acid optimization, LNP formulation, cell-based assay development, and automated high-throughput screening.
Collaborative R&D partnerships for antiviral and RNA therapeutic development
Collaborative research agreements and program partnerships with government agencies and industry to develop nucleic acid-based countermeasures and therapeutics.
Preclinical discovery and optimization services
End-to-end preclinical discovery services including protein engineering, nucleic acid optimization, LNP formulation, cell-based assay development, and automated high-throughput screening.
Expertise Areas
- RNA therapeutics
- Antiviral drug discovery
- Synthetic biology
- Protein engineering
Key Technologies
- Target-activated nucleic acid therapeutic platforms
- Lipid nanoparticle (LNP) delivery
- High-throughput automated screening and lab robotics
- Protein design using molecular dynamics and AI